MARKET

QNRX

QNRX

Quoin Pharmaceuticals Ltd
NASDAQ
0.7201
-0.0301
-4.01%
After Hours: 0.7000 -0.0201 -2.79% 17:05 05/23 EDT
OPEN
0.7503
PREV CLOSE
0.7502
HIGH
0.7700
LOW
0.7043
VOLUME
39.88K
TURNOVER
0
52 WEEK HIGH
12.00
52 WEEK LOW
0.6029
MARKET CAP
2.87M
P/E (TTM)
-0.0859
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at QNRX last week (0513-0517)?
Weekly Report · 3d ago
Weekly Report: what happened at QNRX last week (0506-0510)?
Weekly Report · 05/13 12:27
Quoin Pharmaceuticals on the Brink: Nasdaq Deficiency Notice Threatens Stability and Investor Confidence
TipRanks · 05/11 06:02
Analysts Offer Insights on Healthcare Companies: Zevra Therapeutics (ZVRA), ALX Oncology Holdings (ALXO) and Quoin Pharmaceuticals (QNRX)
TipRanks · 05/10 15:30
Quoin Pharmaceuticals Ltd. Quarterly Report on Form 10-Q for the Quarter Ended March 31, 2024
Press release · 05/10 13:42
QNRX Stock Earnings: Quoin Pharmaceuticals Misses EPS for Q1 2024
Quoin Pharmaceuticals reported earnings per share of -$1.11 for the first quarter of 2024. The company did not report any revenue for the quarter. This was below the analyst estimate for EPS of -76 cents. Quoin reported results for the fourth quarter of 2016.
Investorplace · 05/09 16:53
Quoin Pharmaceuticals Non-GAAP EPS of -$1.11 misses by $0.70
Seeking Alpha · 05/09 14:51
Quoin Pharmaceuticals Q1 EPS $(1.11) Compared With $(4.09) YoY, Quoin Had Approximately $14.7M In Cash & Equivalents As Of March 31, 2024
Benzinga · 05/09 12:36
More
About QNRX
Quoin Pharmaceuticals Ltd, former Cellect Biotechnology Ltd, is an Israel-based specialty pharmaceutical company, focused on developing and commercializing therapeutic products that treat rare and orphan diseases. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.

Webull offers Quoin Pharmaceuticals Ltd - ADR stock information, including NASDAQ: QNRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, QNRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading QNRX stock methods without spending real money on the virtual paper trading platform.